
The NMPA approved SYVIK for certain adults with chronic primary ITP and warm antibody autoimmune hemolytic anemia.
HUTCHMED said China’s National Medical Products Administration approved SYVIK for two autoimmune blood disorders: chronic primary immune thrombocytopenia (ITP) and warm antibody autoimmune hemolytic anemia (wAIHA).
The approvals cover adults with ITP who had an insufficient response to at least one prior therapy, and adults with wAIHA who had an insufficient response to corticosteroids. The company said SYVIK is the first novel Syk inhibitor approved in China.
In the ESLIM-01 ITP trial, the durable response rate was 48.4% with SYVIK and zero with placebo. In the ESLIM-02 wAIHA trial, durable response during weeks 5–24 was 66% with SYVIK, compared with 15% with placebo.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.